actinium has been researched along with Androgen-Independent Prostatic Cancer in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 17 (85.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higaki, Y; Ichikawa, H; Iikuni, S; Nakashima, K; Ono, M; Tarumizu, Y; Watanabe, H | 1 |
| Kim, YI; Lee, DY | 1 |
| Basaran, M; Büyükkaya, F; Civan, C; Isik, EG; Kuyumcu, S; Ozkan, ZG; Sanli, O; Sanli, Y; Simsek, DH | 1 |
| Afshar-Oromieh, A; Birindelli, G; D'Alessandria, C; Drobnjakovic, M; Eiber, M; Gourni, E; Morath, V; Rominger, A; Shi, K; Steiger, K; Weber, W | 1 |
| Gill, HJS; Maheshwari, P; Satapathy, S; Sharma, A; Sood, A | 1 |
| de Blois, E; de Jong, M; De Saint-Hubert, M; Konijnenberg, MW; Nonnekens, J; Roobol, SJ; Ruigrok, EAM; Tamborino, G; van Weerden, WM; Verkaik, N | 1 |
| Bander, NH; Osborne, JR; Ricaurte-Fajardo, A; Stangl-Kremser, J; Subramanian, K; Sun, M; Tagawa, ST | 1 |
| Agrawal, K; Bishnoi, K; Panda, RA; Parida, GK | 1 |
| Bander, NH; Ho, B; Molina, A; Nanus, DM; Nauseef, JT; Osborne, JR; Stangl-Kremser, J; Sternberg, CN; Sun, M; Tagawa, S; Thomas, J | 1 |
| Dizdarevic, S; McCready, R; Vinjamuri, S | 1 |
| Das, CK; Kaur, K; Mittal, BR; Parmar, M; Sood, A; Vadi, SK; Vatsa, R | 1 |
| Gómez de Iturriaga, A; Mínguez Gabiña, P; Mínguez, R; Rodeño, E; Roeske, JC | 1 |
| Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA | 1 |
| Bruchertseifer, F; Custers, JAE; Gerritsen, WR; Haberkorn, U; Janssen, MJR; Kratochwil, C; Kroeze, LI; Looijen-Salamon, MG; Mehra, N; Morgenstern, A; Nagarajah, J; Slootbeek, PHJ; van der Doelen, MJ; van Oort, IM | 1 |
| Das, CK; Mittal, BR; Satapathy, S; Sood, A | 1 |
| Bal, C; Ballal, S; Dwivedi, SN; Sahoo, RK; Tripathi, M; Yadav, MP | 1 |
| Bruchertseifer, F; de Keizer, B; Ezziddin, S; Gerritsen, WR; Gotthardt, M; Heskamp, S; Janssen, MJR; Kratochwil, C; Laarhuis, BI; Ligtenberg, MJL; Mehra, N; Morgenstern, A; Naga, SP; Nagarajah, J; Privé, BM; Slootbeek, PHJ; van der Doelen, MJ; van Kalmthout, LWM; van Oort, IM; Witjes, JA | 1 |
| Bruchertseifer, F; Bulut, OC; Flechsig, P; Giesel, FL; Haberkorn, U; Hein, M; Hohenberger, R; Kratochwil, C; Morgenstern, A; Plinkert, P; Rathke, H | 1 |
| Al Kandari, F; Marafi, F; Naqvi, SAR; Rasheed, R; Usmani, S | 1 |
| Boshomane, TG; Bruchertseifer, F; Knoesen, O; Lawal, IO; Lengana, T; Mokoala, KK; Morgenstern, A; Sathekge, MM; Vorster, M | 1 |
6 review(s) available for actinium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Effects of
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Leukopenia; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia; Treatment Outcome; Xerostomia | 2022 |
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
Topics: Actinium; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Treatment Outcome | 2023 |
Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis.
Topics: Actinium; Dipeptides; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Topics: Actinium; Astatine; Bismuth; Bone Neoplasms; Humans; Lead Radioisotopes; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Thorium | 2020 |
Evolving role of
Topics: Actinium; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Survival Rate | 2021 |
Topics: Actinium; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Theranostic Nanomedicine; Treatment Outcome | 2021 |
14 other study(ies) available for actinium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Radiotheranostics Using a Novel
Topics: Actinium; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclams; Glutamate Carboxypeptidase II; Humans; Ligands; Male; Membrane Glycoproteins; Mice, Inbred ICR; Mice, SCID; Precision Medicine; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography; Urea; Xenograft Model Antitumor Assays | 2021 |
225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: A Single-Center Experience.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Tumor Microenvironment | 2021 |
Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy.
Topics: Actinium; Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Topics: Actinium; Cell Line, Tumor; Dipeptides; DNA; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2022 |
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Topics: Actinium; Humans; Lymphocytes; Male; Neutrophils; Prognosis; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2023 |
225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.
Topics: Actinium; Alpha Particles; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2020 |
Microdosimetry-based determination of tumour control probability curves for treatments with
Topics: Actinium; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Male; Monte Carlo Method; Neoplasm Metastasis; Probability; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiotherapy Dosage | 2020 |
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Xerostomia | 2021 |
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with
Topics: Actinium; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Topics: Actinium; Dipeptides; DNA Damage; Heterocyclic Compounds, 1-Ring; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing
Topics: Actinium; Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Salivary Glands; Surgery, Computer-Assisted; Therapeutic Irrigation; Xerostomia | 2019 |
225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Middle Aged; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiopharmaceuticals; Reference Standards | 2019 |
Treatment of brain metastases of castration-resistant prostate cancer with
Topics: Actinium; Brain Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2019 |